Free Trial

Amgen (AMGN) Competitors

Amgen logo
$273.08 -1.32 (-0.48%)
Closing price 09/16/2025 04:00 PM Eastern
Extended Trading
$273.60 +0.53 (+0.19%)
As of 09/16/2025 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AMGN vs. GILD, MRNA, VRTX, ABBV, BMY, JNJ, LLY, MRK, PFE, and ALNY

Should you be buying Amgen stock or one of its competitors? The main competitors of Amgen include Gilead Sciences (GILD), Moderna (MRNA), Vertex Pharmaceuticals (VRTX), AbbVie (ABBV), Bristol Myers Squibb (BMY), Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK), Pfizer (PFE), and Alnylam Pharmaceuticals (ALNY). These companies are all part of the "medical" sector.

Amgen vs. Its Competitors

Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

In the previous week, Amgen had 13 more articles in the media than Gilead Sciences. MarketBeat recorded 60 mentions for Amgen and 47 mentions for Gilead Sciences. Gilead Sciences' average media sentiment score of 1.50 beat Amgen's score of 1.44 indicating that Gilead Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amgen
51 Very Positive mention(s)
0 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Gilead Sciences
36 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Very Positive

76.5% of Amgen shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 0.7% of Amgen shares are owned by insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Amgen has a beta of 0.49, meaning that its share price is 51% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.36, meaning that its share price is 64% less volatile than the S&P 500.

Gilead Sciences has a net margin of 21.86% compared to Amgen's net margin of 18.96%. Amgen's return on equity of 174.71% beat Gilead Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Amgen18.96% 174.71% 13.12%
Gilead Sciences 21.86%50.99%17.24%

Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.5%. Gilead Sciences pays an annual dividend of $3.16 per share and has a dividend yield of 2.9%. Amgen pays out 77.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences pays out 62.9% of its earnings in the form of a dividend. Amgen has increased its dividend for 14 consecutive years and Gilead Sciences has increased its dividend for 10 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$33.42B4.40$4.09B$12.2322.33
Gilead Sciences$28.75B4.78$480M$5.0222.08

Amgen currently has a consensus target price of $304.43, indicating a potential upside of 11.48%. Gilead Sciences has a consensus target price of $116.04, indicating a potential upside of 4.68%. Given Amgen's higher possible upside, equities analysts clearly believe Amgen is more favorable than Gilead Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amgen
2 Sell rating(s)
12 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.24
Gilead Sciences
0 Sell rating(s)
6 Hold rating(s)
18 Buy rating(s)
3 Strong Buy rating(s)
2.89

Summary

Amgen beats Gilead Sciences on 11 of the 20 factors compared between the two stocks.

Get Amgen News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMGN vs. The Competition

MetricAmgenMED IndustryMedical SectorNASDAQ Exchange
Market Cap$147.73B$3.12B$5.73B$10.31B
Dividend Yield3.47%2.36%5.90%4.63%
P/E Ratio22.3321.1675.8626.51
Price / Sales4.40446.35528.72123.58
Price / Cash9.0345.4037.1760.46
Price / Book24.989.6212.796.29
Net Income$4.09B-$53.28M$3.28B$270.51M
7 Day Performance-1.95%1.01%0.81%1.95%
1 Month Performance-7.89%4.58%4.60%6.33%
1 Year Performance-17.94%8.35%70.39%25.62%

Amgen Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMGN
Amgen
4.6658 of 5 stars
$273.08
-0.5%
$304.43
+11.5%
-18.5%$147.73B$33.42B22.3328,000Positive News
GILD
Gilead Sciences
4.9382 of 5 stars
$115.52
+0.4%
$115.39
-0.1%
+33.3%$143.34B$28.75B23.0117,600Positive News
Analyst Forecast
Insider Trade
MRNA
Moderna
4.5233 of 5 stars
$24.51
-2.5%
$42.88
+75.0%
-64.1%$9.54B$3.24B-3.265,800News Coverage
VRTX
Vertex Pharmaceuticals
4.8981 of 5 stars
$393.59
-0.6%
$497.10
+26.3%
-20.0%$100.87B$11.02B28.126,100Positive News
ABBV
AbbVie
4.7885 of 5 stars
$209.21
-1.6%
$214.95
+2.7%
+10.5%$369.57B$56.33B99.6255,000Trending News
Analyst Forecast
Analyst Revision
BMY
Bristol Myers Squibb
4.8904 of 5 stars
$46.47
-1.4%
$56.38
+21.3%
-7.4%$94.58B$48.30B18.7434,100Positive News
JNJ
Johnson & Johnson
4.6831 of 5 stars
$177.88
-0.3%
$176.29
-0.9%
+5.7%$427.90B$88.82B19.00138,100Trending News
Analyst Upgrade
LLY
Eli Lilly and Company
4.9979 of 5 stars
$736.36
+1.3%
$950.17
+29.0%
-17.4%$695.19B$45.04B48.0147,000Trending News
Analyst Forecast
MRK
Merck & Co., Inc.
4.9972 of 5 stars
$83.87
-1.0%
$107.44
+28.1%
-31.3%$209.53B$64.17B12.9375,000Positive News
PFE
Pfizer
4.9867 of 5 stars
$24.47
-1.7%
$28.12
+14.9%
-20.6%$139.10B$63.63B13.0181,000Trending News
ALNY
Alnylam Pharmaceuticals
3.7828 of 5 stars
$454.64
+0.6%
$417.38
-8.2%
+70.6%$59.59B$2.25B-184.042,230Positive News
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:AMGN) was last updated on 9/17/2025 by MarketBeat.com Staff
From Our Partners